Recce Pharmaceuticals (ASX:RCE) has secured human research ethics committee approval to allow up to 20 additional patients in its phase two clinical study to access Recce 327, a topical gel designed for diabetic foot infections (DFI), according to a Tuesday filing with the Australian bourse.
The study will run concurrently with Recce's phase three trial in Indonesia, which is expected to deliver results later in the year, with regulatory approval and commercial launch anticipated in the first half of 2026, the filing said.
Both studies aim to generate additional data to support future regulatory submissions, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。